{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"100"},{"groupId":"OG002","spread":"0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"LAG525, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"100"},{"groupId":"OG002","spread":"0.71","value":"99.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"PDR001, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.80","value":"99.4"},{"groupId":"OG002","spread":"1.47","value":"99.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"LAG525, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.80","value":"99.4"},{"groupId":"OG002","spread":"1.47","value":"99.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"PDR001, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"100"},{"groupId":"OG002","spread":"0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"LAG525, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"100"},{"groupId":"OG002","spread":"0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"PDR001, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.26","value":"99.3"},{"groupId":"OG002","spread":"1.99","value":"99.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"LAG525, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.26","value":"99.3"},{"groupId":"OG002","spread":"1.99","value":"99.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"PDR001, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.08","value":"96.5"},{"groupId":"OG001","spread":"0","value":"100"},{"groupId":"OG002","spread":"0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"LAG525, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.21","value":"98.4"},{"groupId":"OG001","spread":"0","value":"100"},{"groupId":"OG002","spread":"0","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"PDR001, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day).\n\nThe RDI of both study drugs is reported for each tumor type.","dispersionType":"Standard Deviation","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From start of treatment until end of treatment, assessed up to 2.6 years.","title":"Phase 2: Relative Dose Intensity (RDI) of LAG525 and PDR001","type":"SECONDARY","unitOfMeasure":"percentage"}